VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED

VERTEX PHARMACEUTICALS INCORPORATED

No trades
See on Supercharts

Price target

10,325.850.000.00%
The 28 analysts offering 1 year price forecasts for VRTX have a max estimate of — and a min estimate of —.

Analyst rating

Based on 36 analysts giving stock ratings to VRTX in the past 3 months.

EPS

Reported
Estimate
Reported
Estimate
Surprise

Revenue

Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


VRTX EPS for the last quarter is 86.30 MXN despite the estimation of 80.35 MXN. In the next quarter EPS is expected to reach 82.39 MXN. Track more of VERTEX PHARMACEUTICALS INCORPORATED financials and stay on top of what is up with the company.
In the next quarter VERTEX PHARMACEUTICALS INCORPORATED revenue is expected to reach ‪56.62 B‬ MXN. Check out VERTEX PHARMACEUTICALS INCORPORATED revenue and earnings and make informed decisions.
According to analysts, VRTX price target is 10,325.85 MXN with a max estimate of 12,238.26 MXN and a min estimate of 6,607.03 MXN. Check if this forecast comes true in a year, meanwhile watch VERTEX PHARMACEUTICALS INCORPORATED stock price chart and keep track of the current situation with VRTX news and stock market news.
We've gathered opinions of 36 analysts rating VRTX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.